Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201209116 Principal Investigator: Linette, Gerald
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib versus Vemurafenib Plus Gdc-0973 in Previously Untreated BRAFV600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma
Phase: III Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this study is to compare the effects, good and/or bad, of GDC-0973 and vemurafenib with vemurafenib alone on patients and their melanoma, to find out which is better.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)